Model for assessing human papillomavirus vaccination strategies

被引：349

作者：

Elbasha, Elamin H. ^{[1
]}

Dasbach, Erik J. ^{[1
]}

Insinga, Ralph P. ^{[1
]}

机构：

[1] Merck Res Labs, N Wales, PA 19454 USA

来源：

EMERGING INFECTIOUS DISEASES | 2007年 / 13卷 / 01期

关键词：

D O I：

10.3201/eid1301.060438

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We present a transmission dynamic model that can assess the epidemiologic consequences and cost-effectiveness of alternative strategies of administering a prophylactic quadrivalent (types 6/11/16/18) human papillomavirus (HPV) vaccine in a setting of organized cervical cancer screening in the United States. Compared with current practice, vaccinating girls before the age of 12 years would reduce the incidence of genital warts (83%) and cervical cancer (78%) due to HPV 6/11/16/18. The incremental cost-effectiveness ratio (ICER) of augmenting this strategy with a temporary catch-up program for 12- to 24-year-olds was US $4,666 per quality-adjusited life year (QALY) gained. Relative to other commonly accepted healthcare programs, vaccinating girls and women appears cost-effective. Including men and boys in the program was the most effective strategy, reducing the incidence of genital warts, cervical intraepithelial neoplasia, and cervical cancer by 97%, 91%, and 91%, respectively. The ICER of this strategy was $45,056 per QALY.

引用

页码：28 / 41

页数：14

共 72 条

[1]

Andersen B L, 1996, J Natl Cancer Inst Monogr, P65

[2]

[Anonymous], COST EFF AN REG

[3] Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses [J].